• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Agenus Inc.

    2/21/24 4:16:50 PM ET
    $AGEN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $AGEN alert in real time by email
    SC 13G 1 p24-0956sc13g.htm AGENUS INC
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
     
     
    SCHEDULE 13G
     
    Under the Securities Exchange Act of 1934
    (Amendment No.  )*
     

    Agenus Inc.

    (Name of Issuer)
     

    Common Stock, par value $0.01 per share

    (Title of Class of Securities)
     

    00847G705

    (CUSIP Number)
     

    February 20, 2024

    (Date of Event Which Requires Filing of this Statement)
     
     
    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
     
    ¨ Rule 13d-1(b)
    ý Rule 13d-1(c)
    ¨ Rule 13d-1(d)
     
    (Page 1 of 8 Pages)

     

    ______________________________

    *The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

    CUSIP No. 00847G70513GPage 2 of 8 Pages

     

     

    1

    NAME OF REPORTING PERSON

     

    Point72 Asset Management, L.P.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    28,268,112

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    28,268,112

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    28,268,112

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.8%

    12

    TYPE OF REPORTING PERSON

    PN

             

     

     

    CUSIP No. 00847G70513GPage 3 of 8 Pages

     

     

    1

    NAME OF REPORTING PERSON

     

    Point72 Capital Advisors, Inc.

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    28,268,112

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    28,268,112

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    28,268,112

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.8%

    12

    TYPE OF REPORTING PERSON

    CO

             

     

     

    CUSIP No. 00847G70513GPage 4 of 8 Pages

     

     

    1

    NAME OF REPORTING PERSON

     

    Cubist Systematic Strategies, LLC

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    Delaware

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    388

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    388

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    388

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    <0.1%

    12

    TYPE OF REPORTING PERSON

    OO

             

     

     

    CUSIP No. 00847G70513GPage 5 of 8 Pages

     

     

    1

    NAME OF REPORTING PERSON

     

    Steven A. Cohen

    2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

    (a) ¨

    (b) x

    3 SEC USE ONLY
    4

    CITIZENSHIP OR PLACE OF ORGANIZATION

    United States

    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY
    EACH
    REPORTING
    PERSON WITH
    5

    SOLE VOTING POWER

    0

    6

    SHARED VOTING POWER

    28,268,500

    7

    SOLE DISPOSITIVE POWER

    0

    8

    SHARED DISPOSITIVE POWER

    28,268,500

    9

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

    28,268,500

    10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES ¨
    11

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

    6.8%

    12

    TYPE OF REPORTING PERSON

    IN

             

     

     

    CUSIP No. 00847G70513GPage 6 of 8 Pages

      

    Item 1(a). Name of Issuer.
      Agenus Inc. (the “Issuer”).

     

    Item 1(b). Address of Issuer's Principal Executive Offices.
      3 Forbes Road, Lexington, Massachusetts 02421.

     

    Item 2(a). Name of Person Filing.
      This statement is filed by: (i) Point72 Asset Management, L.P. (“Point72 Asset Management”) with respect to common stock, par value $0.01 per share (“Shares”), of the Issuer held by Point72 Associates, LLC, an investment fund it manages (“Point72 Associates”); (ii) Point72 Capital Advisors, Inc. (“Point72 Capital Advisors Inc.”) with respect to Shares held by Point72 Associates; (iii) Cubist Systematic Strategies, LLC (“Cubist Systematic Strategies”) with respect to Shares held by an investment fund it manages; and (iv) Steven A. Cohen (“Mr. Cohen”) with respect to Shares beneficially owned by Point72 Asset Management, Point72 Capital Advisors Inc., and Cubist Systematic Strategies.
       
      Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic Strategies, and Mr. Cohen have entered into a Joint Filing Agreement, a copy of which is filed with this Schedule 13G as Exhibit 99.1, pursuant to which they have agreed to file this Schedule 13G jointly in accordance with the provisions of Rule 13d-1(k) of the Act.

     

    Item 2(b). Address of Principal Business Office.
      The address of the principal business office of (i) Point72 Asset Management, Point72 Capital Advisors Inc., and Mr. Cohen is 72 Cummings Point Road, Stamford, CT 06902; and (ii) Cubist Systematic Strategies is 55 Hudson Yards, New York, NY 10001.

     

    Item 2(c). Place of Organization.
      Point72 Asset Management is a Delaware limited partnership. Point72 Capital Advisors Inc. is a Delaware corporation. Cubist Systematic Strategies is a Delaware limited liability company.  Mr. Cohen is a United States citizen.

     

    Item 2(d). Title of Class of Securities.
      Common Stock, par value $0.01 per share.

     

    Item 2(e). CUSIP Number.
      00847G705

     

    Item 3. If this Statement is Filed Pursuant to §§ 240.13d-1(b) or 240.13d-2(b), or (c), check whether the Person Filing is a:
      Not applicable.

     

    Item 4. Ownership.
      The information required by Items 4(a) – (c) is set forth in Rows (5) – (11) of the cover page for each Reporting Person hereto and is incorporated herein by reference for each Reporting Person.  Such information is as of the close of business on February 20, 2024.
       

     

    CUSIP No. 00847G70513GPage 7 of 8 Pages

      

      Point72 Asset Management, Point72 Capital Advisors Inc., Cubist Systematic Strategies, and Mr. Cohen own directly no Shares. Pursuant to an investment management agreement, Point72 Asset Management maintains investment and voting power with respect to the securities held by Point72 Associates. Point72 Capital Advisors Inc. is the general partner of Point72 Asset Management. Pursuant to an investment management agreement, Cubist Systematic Strategies maintains investment and voting power with respect to the securities held by an investment fund it manages.  Mr. Cohen controls each of Point72 Asset Management, Point72 Capital Advisors Inc., and Cubist Systematic Strategies.   The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Shares reported herein.
       
      The aggregate percentage of the Shares reported to be beneficially owned by each Reporting Person is based on 414,246,272 Shares outstanding which is the sum of: (i) 399,246,272 Shares outstanding as of February 9, 2024, as reported in the Issuer’s Preliminary Proxy Statement on Schedule 14A filed with the Securities and Exchange Commission on February 15, 2024; and (ii) 15,000,000 Shares purchased by Point72 Associates in the at the market offering by the Issuer.

     

    Item 5. Ownership of Five Percent or Less of a Class.
      If this statement is being filed to report the fact that as of the date hereof the Reporting Person has ceased to be the beneficial owner of more than 5 percent of the class of securities, check the following [ ].

     

    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
      Point72 Associates has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5 percent of the outstanding Shares.

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
      Not applicable.

     

    Item 8. Identification and Classification of Members of the Group.
      Not applicable.

     

    Item 9. Notice of Dissolution of Group.
      Not applicable.

     

    Item 10. Certification.
      By signing below each Reporting Person certifies that, to the best of its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

     

     

    CUSIP No. 00847G70513GPage 8 of 8 Pages

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, each of the undersigned certifies that the information set forth in this statement is true, complete and correct.

     

    Date: February 21, 2024  
      POINT72 ASSET MANAGEMENT, L.P.
       
      By: /s/ Jason M. Colombo
      Name:  Jason M. Colombo
      Title:    Authorized Person
       
       
      POINT72 CAPITAL ADVISORS, INC.
       
      By: /s/ Jason M. Colombo
      Name:  Jason M. Colombo
      Title:    Authorized Person
       
       
      CUBIST SYSTEMATIC STRATEGIES, LLC
       
      By: /s/ Jason M. Colombo
      Name:  Jason M. Colombo
      Title:    Authorized Person
       
      STEVEN A. COHEN
       
      By: /s/ Jason M. Colombo
      Name:  Jason M. Colombo
      Title:    Authorized Person

     

    Get the next $AGEN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AGEN

    DatePrice TargetRatingAnalyst
    7/19/2024$35.00 → $8.00Outperform → Neutral
    Robert W. Baird
    7/18/2024Outperform → Mkt Perform
    William Blair
    7/18/2024$9.00Buy → Neutral
    H.C. Wainwright
    6/6/2023$8.00Outperform
    Robert W. Baird
    6/6/2023$60.00 → $80.00Outperform
    Robert W. Baird
    2/28/2023$8.00Buy
    H.C. Wainwright
    9/28/2022$5.00Outperform
    SMBC Nikko
    3/2/2022$12.00 → $14.00Buy
    HC Wainwright & Co.
    More analyst ratings

    $AGEN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Agenus downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded Agenus from Outperform to Neutral and set a new price target of $8.00 from $35.00 previously

      7/19/24 7:27:15 AM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Agenus downgraded by William Blair

      William Blair downgraded Agenus from Outperform to Mkt Perform

      7/18/24 1:59:35 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Agenus downgraded by H.C. Wainwright with a new price target

      H.C. Wainwright downgraded Agenus from Buy to Neutral and set a new price target of $9.00

      7/18/24 12:35:32 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AGEN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Agenus Presents New Data at ASCO Highlighting Botensilimab's Immune Activation in MSS Colorectal Cancer

      Study shows botensilimab "switches on" the body's own T-cells to attack a common, treatment-resistant form of colorectal cancer Agenus Inc. (NASDAQ:AGEN), a leader in immuno-oncology, today presented new translational data at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. The study demonstrates that botensilimab-based therapy induces a robust and persistent T cell immune response in microsatellite stable (MSS), or mismatch repair proficient (pMMR), metastatic colorectal cancer (mCRC)—a tumor type traditionally resistant to immunotherapy and representing approximately 85-95% of all colorectal cancers. T cells are key immune cells capable of recognizing and attacking

      5/30/25 7:30:00 AM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Agenus Announces New Data from Expanded MSS Metastatic Colorectal Cancer Cohort to be Presented at ESMO GI 2025

      Presenting new data in the most mature readout to date, with 60% more patients and reported median and 2-year overall survival. Agenus Inc. ("Agenus" or the Company") (NASDAQ:AGEN), a leader in immuno-oncology, today announced new data from its ongoing Phase 1 trial evaluating botensilimab and balstilimab (BOT/BAL) in patients with microsatellite stable (MSS) metastatic colorectal cancer (mCRC) at the 2025 European Society for Medical Oncology (ESMO) Gastrointestinal Cancers Congress in Barcelona, Spain. A poster presentation will feature updated findings from an expanded cohort of 123 patients, incorporating additional participants and extended follow-up to further assess clinical activ

      5/15/25 10:40:00 AM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Agenus Reports Q1 2025 Financial Results and Key Business Updates

      BOT/BAL Achieves Breakthrough Response Rates in MSS Cancers — Oral AACR Data Spotlight Pan-Tumor Neoadjuvant Success Seasoned Leader Onboard to Accelerate BOT/BAL Toward Registration Milestones Near-Term Capital Transaction Poised to Bolster Liquidity Agenus Inc. ("Agenus" or the "Company") (NASDAQ:AGEN), a leader in immuno-oncology, today reported financial and operational results for the first quarter of 2025, and shared key clinical and strategic milestones supporting the advancement of its botensilimab (BOT) and balstilimab (BAL) program. "The growing strength of our BOT/BAL data across multiple hard-to-treat cancers reinforces our conviction in its transformative potential and

      5/12/25 7:30:00 AM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AGEN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Armen Garo H bought $324,050 worth of shares (500,000 units at $0.65) (SEC Form 4)

      4 - AGENUS INC (0001098972) (Issuer)

      2/15/24 6:59:48 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Wiinberg Ulf bought $19,000 worth of shares (25,000 units at $0.76), increasing direct ownership by 25% to 124,063 units (SEC Form 4)

      4 - AGENUS INC (0001098972) (Issuer)

      11/17/23 4:22:11 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AGEN
    SEC Filings

    See more
    • SEC Form S-3 filed by Agenus Inc.

      S-3 - AGENUS INC (0001098972) (Filer)

      5/12/25 5:09:12 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 10-Q filed by Agenus Inc.

      10-Q - AGENUS INC (0001098972) (Filer)

      5/12/25 4:50:40 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Agenus Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - AGENUS INC (0001098972) (Filer)

      5/12/25 7:32:09 AM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AGEN
    Financials

    Live finance-specific insights

    See more
    • Agenus Reports Q1 2025 Financial Results and Key Business Updates

      BOT/BAL Achieves Breakthrough Response Rates in MSS Cancers — Oral AACR Data Spotlight Pan-Tumor Neoadjuvant Success Seasoned Leader Onboard to Accelerate BOT/BAL Toward Registration Milestones Near-Term Capital Transaction Poised to Bolster Liquidity Agenus Inc. ("Agenus" or the "Company") (NASDAQ:AGEN), a leader in immuno-oncology, today reported financial and operational results for the first quarter of 2025, and shared key clinical and strategic milestones supporting the advancement of its botensilimab (BOT) and balstilimab (BAL) program. "The growing strength of our BOT/BAL data across multiple hard-to-treat cancers reinforces our conviction in its transformative potential and

      5/12/25 7:30:00 AM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Agenus to Provide Corporate Update and First Quarter 2025 Financial Report

      Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the Company will release its first quarter 2025 financial results before the market opens on Monday, May 12th. Agenus executives will host a conference call and webcast at 8:30 a.m. ET that morning to discuss the results and provide a corporate update. Conference Call: To access dial-in numbers, please register here. Conference ID: 73242 A live webcast and replay of the conference call will be accessible on the company's website at https://investor.agenusbio.com/events-and-presentations and via https://events.q4inc.com/attendee/903911751. About Agenus Agenu

      4/29/25 7:30:00 AM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Agenus Reports Q4 and Year-End 2024 Results; Strategic Operational Improvements and Significant Cost Reductions Enhance Sustainability of Promising BOT/BAL Program

      Agenus Inc. ("Agenus" or the "Company") (NASDAQ:AGEN), an immuno-oncology company advancing innovative cancer therapies, today reported financial and operational results for Q4 and full-year 2024, highlighting strategic measures to substantially reduce operational costs while preserving and enhancing the potential of its leading BOT/BAL program. "In line with our strategic objectives, we significantly reduced our annualized operational burn rate. We anticipate further reducing our annual burn to an annualized rate of approximately $50 million by mid-2025 through the externalization of development costs associated with BOT/BAL, monetization of our CMC assets, and other reductions in operati

      3/11/25 7:30:00 AM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AGEN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Agenus Inc.

      SC 13G/A - AGENUS INC (0001098972) (Subject)

      11/14/24 7:58:18 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Agenus Inc.

      SC 13G/A - AGENUS INC (0001098972) (Subject)

      11/14/24 9:21:26 AM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Agenus Inc. (Amendment)

      SC 13G/A - AGENUS INC (0001098972) (Subject)

      6/10/24 12:15:17 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AGEN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Officer Armen Garo H was granted 4,700 shares, increasing direct ownership by 3% to 185,750 units (SEC Form 4)

      4 - AGENUS INC (0001098972) (Issuer)

      5/20/25 4:05:04 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Director Buell Jennifer was granted 581 shares, increasing direct ownership by 3% to 19,738 units (SEC Form 4)

      4 - AGENUS INC (0001098972) (Issuer)

      5/6/25 5:21:12 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Officer Armen Garo H was granted 5,260 shares, increasing direct ownership by 3% to 181,060 units (SEC Form 4)

      4 - AGENUS INC (0001098972) (Issuer)

      5/5/25 4:05:04 PM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $AGEN
    Leadership Updates

    Live Leadership Updates

    See more
    • Agenus Announces Appointment of Tom Harrison to Board of Directors

      Advertising Veteran Tapped to Elevate Awareness of Agenus and Its Innovative Pipeline Agenus Inc. (NASDAQ:AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced the appointment of Tom Harrison to its Board of Directors. Mr. Harrison brings a wealth of experience and a proven track record in healthcare advertising, branding, and strategic advising. Tom Harrison's Background Highlights: Chairman Emeritus of Diversified Agency Services (DAS), Omnicom Group Inc.: Harrison led the world's largest group of marketing services companies, overseeing an unparalleled range of services including public relations, crisis management, bran

      8/8/24 7:00:00 AM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Agenus Announces Appointment of Dr. Jennifer Buell to Its Board of Directors

      Strategic leadership to drive next phase of growth for the company Agenus Inc. ("Agenus") (NASDAQ:AGEN), a leader in developing novel immunological agents to treat various cancers, is pleased to announce the appointment of Dr. Jennifer Buell to its Board of Directors, on June 11, 2024, effective immediately. Dr. Buell will maintain her active and ongoing role as the President and CEO of MiNK Therapeutics, in addition to her responsibilities as Chairman of the Executive Council at Agenus. Her continued leadership at MiNK ensures a seamless integration of strategic insights across both organizations, enhancing our collaborative efforts to innovate and deliver breakthrough cancer therapies.

      6/17/24 7:00:00 AM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Agenus Expands Executive Leadership Team

      Robin Taylor, MBA, Ph.D., Appointed Chief Commercial Officer Homa Yeganegi Appointed Chief Product Strategy and Global Medical Affairs Officer Stephanie Fagan Appointed Chief Communications Officer Immuno-oncology leader, Agenus Inc. ("Agenus") (NASDAQ:AGEN), today announced the appointment of Robin Taylor, Ph.D., Homa Yeganegi and Stephanie Fagan to its executive team. The newly appointed leaders bring a wealth of industry experience to drive the company's next phase of growth in the development and planned commercialization of botensilimab and a deep pipeline of immuno-oncology programs, which offer potential breakthroughs in cancer therapeutics. Chief Commercial Officer, Robin Ta

      7/20/23 7:30:00 AM ET
      $AGEN
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care